- Bio-Techne’s Q4 revenues surpassed estimates, but adjusted EPS declined year-over-year, indicating mixed financial performance.
- Benchmark reiterated a “Hold” rating on Bio-Techne due to the pending acquisition by Merck KGaA, which limits stock price movement.
- The acquisition by Merck KGaA at $73 per share is a primary driver for Bio-Techne’s stock price, keeping it close to the offer value despite strong organic growth in some segments.
Bio-Techne (NASDAQ: TECH) is a leading company specializing in the development and sale of essential life science reagents, instruments, and services for the research and clinical diagnostics markets. Its innovative products are crucial for supporting advancements in biopharma and diagnostics. The company is currently undergoing a significant acquisition by Merck KGaA (XTRA: MRK) in a substantial cash transaction.
On August 19, 2026, the prominent analyst firm Benchmark reiterated its “Hold” rating on Bio-Techne. A “Hold” rating typically indicates that analysts anticipate the stock to perform in line with the broader market, without significant upward or downward movement. At the time of this announcement, Bio-Techne’s stock price stood at $72.47.
This rating follows Bio-Techne’s recent fourth-quarter earnings report. As highlighted by Zacks Investment Research, Bio-Techne’s revenues increased by 1% to $321.2 million, successfully surpassing market estimates. However, its adjusted earnings per share (EPS) of $0.52, while meeting forecasts, represented a 1.9% decline from the previous year, indicating a mixed financial performance.
The company’s GAAP EPS for the quarter was $0.35. GAAP, or Generally Accepted Accounting Principles, serves as the standard accounting framework. This result marks a notable improvement from a loss of $0.11 in the same quarter last year, signaling a positive shift in the company’s actual profitability.
The ongoing acquisition by Merck KGaA remains a key factor, featuring a cash offer of $73 per share. With Bio-Techne’s stock trading near $72.50, its price is closely tied to this offer, effectively limiting its potential movement. This specific market situation strongly supports a “Hold” rating, even in light of robust organic revenue growth of 8% observed in its Diagnostics and Spatial Biology segments.
